www.nextgensciences.com
NextGen Group PLC (or ‘the “Company”) AGM Statement Anthony Rhatigan, Chairman of NextGen Group PLC, the AIM-listed “gene-to-protein” company, will make the following comments at the Company’s Annual General Meeting being held today at 10.00 am. “I am pleased to report that, following the hiring of the company’s US sales force in March, the Company has continued to improve its sales pipeline both in size and development. The Company uses a 10 stage monitoring process to evaluate sales progress. Sales invoiced so far this year, plus orders in progress, are expected to approximately equal the revenue generated in the whole of 2005. Practice in the industry would indicate that it is reasonable to expect more sales in the latter half of the year than the first. “The Company has continued to develop its business strategy and is finding that there is significant scope for the products and services it produces, not only in its current target markets of drug discovery and diagnostics but beyond in areas such as biofuels, bioremediation and vaccine development. The Company continues to advance negotiations with other complementary companies in the drug discovery arena with a view to broadening its coverage of the drug discovery market and increasing the number of products it can sell into that market.” For further information please contact: Dr James G Heffernan CEO, Nextgen Group plc 07736 130942 Mike Wort, Anna Dunphy MC Bio-Communications 020 7744 7711 Jonathan Wright/Nicola Marrin Seymour Pierce Limited 020 7107 8000
If you can’t open this electronic message, visit www.nextgensciences.com
about us>
© NextGen Sciences Ltd 2006, All rights reserved If this information is not of interest to you, and you no longer wish to receive press releases, we apologise for any inconvenience caused. To be removed from further emails please click here